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Background: Spreading resistance of Plasmodium falciparum to existing drugs calls for the search for novel
anti-malarial drugs and combinations for the treatment of falciparum malaria.
Methods: In vitro and ex vivo investigations were conducted with fresh P. falciparum field isolates and
culture-adapted P. falciparum clones to evaluate the anti-malarial potential of mirincamycin, a lincosamide, alone
and in combination with tafenoquine (TQ), dihydroartemisinin (DHA), and chloroquine (CQ). All samples were
tested in a histidine-rich protein 2 (HRP2) drug susceptibility assay.
Results: Interaction analysis showed additive to synergistic interaction profiles with these potential partner
drugs, with an overall geometric mean fractional inhibitory concentration at 50% inhibition (FIC50) of 0.78,
0.80 and 0.80 for mirincamycin with TQ, DHA, and CQ, respectively. Antagonism was not found in any of the
tested field isolates or clones. The strongest tendency toward synergy (i.e. the lowest FIC) was seen with a
combination ratio of 1:0.27 to 1:7.2 (mean 1:2.7) for the combination with tafenoquine. The optimal
combination ratios for DHA and CQ were 1:444.4 to 1:36,000 (mean 1:10,755.5) and 1:2.7 to 1:216 (mean
1:64.5), respectively. No evidence of an activity correlation (i.e. potential cross-resistance) with DHA,
mefloquine, quinine or chloroquine was seen whereas a significant correlation with the activity of
clindamycin and azithromycin was detected.
Conclusions: Mirincamycin combinations may be promising candidates for further clinical investigations in the
therapy and prophylaxis of multidrug-resistant falciparum malaria or in combination with 4 or 8-aminoquinolines for
the treatment and relapse prevention of vivax malaria.
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Artemisinin-based combination therapy (ACT) has been
adopted as first-line treatment for Plasmodium falciparum
malaria in virtually all malaria-endemic countries. In the
view of spreading anti-malarial drug resistance and the
emergence of the first cases of compromised susceptibility
to artemisinins along the Thai-Cambodian border the de-
velopment of novel compounds and combinations for the
treatment of falciparum malaria has become an issue of
utmost importance [1,2]. First studies conducted in 1969
and 1970 in rhesus monkeys infected with Plasmodium
cynomolgi, a malaria parasite of monkeys similar to Plasmo-
dium vivax, have shown that mirincamycin, a synthetically-
produced lincosamide antibiotic similar to clindamycin, has
substantial antiplasmodial activity for prophylaxis as well as
for radical cure in animal models [3,4]. Moreover in the
above-mentioned P. cynomolgi model mirincamycin was
shown to be superior compared to clindamycin in both,
prophylaxis and radical cure. In 1985 Schmidt et al.
showed that concomitant administration of mirincamy-
cin improved the hypnozoitocidal efficacy of prima-
quine in a P. cynomolgi model suggesting that the
primaquine dose required for radical cure could be re-
duced by one-half to two-thirds by coadministration
with mirincamycin [5]. In 2010, Held et al. [6] assessed
the in vitro activity of mirincamycin in P. falciparum
field isolates from Gabon and indicated that mirincamy-
cin is more active than the comparator drugs clindamy-
cin and doxycycline. In Gabon, the observed mean IC50
measure after six days of incubation was 10,000-fold
lower than on day 3, suggesting a slow onset of action
(delayed death phenomenon) as previously described
for several other antibiotics [6-8]. A recent study by
Khemawoot et al. found a more than 100-fold increased
potency against field isolates of P. falciparum cultured
ex vivo in primate plasma compared to in vitro investiga-
tions with the W2 clone [9]. A challenge for the radical
cure of P. vivax remains the haemolytic toxicity of
primaquine in G6PD-deficient individuals. Earlier stud-
ies suggest that mirincamycin may improve the efficacy
of 8-aminoquinolines, thereby potentially allowing for
lower doses and reducing toxicity when given in com-
bination [5].
Therefore, mirincamycin has been investigated as a
promising combination partner for prophylaxis and treat-
ment of falciparum malaria.Methods
Study area
The study was carried out at the MARIB (Malaria Re-
search Initiative Bandarban) field site in Bandarban in
southeastern Bangladesh and at the laboratories of the
Medical University of Vienna, Austria.Ethics
Written informed consent was obtained from all study
participants or their legal representatives and the study
protocol was approved by the Ethical Review Committees
of the ICDDR,B and the Medical University of Vienna.
Sampling
Blood samples were taken from male and non-pregnant
female patients aged 8 to 65 years, presenting with micro-
scopically confirmed P. falciparum monoinfections and
parasite densities between 1,000 and 100,000 asexual para-
sites per μl. Blood samples exceeding 1% parasitemia were
diluted with uninfected red blood cells before testing.
Pregnant or breastfeeding women and patients with anti-
malarial drug therapy in the preceding 30 days were ex-
cluded from participation.
Drug susceptibility testing
Mirincamycin (4’-trans-mirincamycin hydrochloride, mo-
lecular weight [MW] 475.47) was provided by Richard
Westerman (Maldevco), tafenoquine (MW 463.49) by
GlaxoSmithKline (GSK), clindamycin hydrochloride (MW
461.44), azithromycin (MW 748.98), dihydroartemisinin
(MW 284.3), chloroquine diphosphate (MW 515.90), quin-
ine sulphate (MW 782.96) and mefloquine hydrochloride
(MW 414.77) were obtained from Sigma Aldrich. All drugs
were dissolved in 70% ethanol to obtain a 1 mg/ml stock
solution.
All samples were cultured for 72 hours to allow for a
direct comparison among all test substances and combina-
tions and growth inhibition assessed using the histidine-
rich-protein 2 (HRP2) in vitro drug susceptibility assay.
The culture and enzyme linked immunosorbent assay
(ELISA) were performed as previous described [8,10,11].
To investigate interaction profiles and most effective ratio
of concentrations of mirincamycin in combination with
standard anti-malarials, fresh P. falciparum field isolates
and culture-adapted P. falciparum clones K1 (chloroquine-
resistant) and 3D7 (chloroquine-sensitive) were tested in
checkerboard assays and data analysis was done as previ-
ously described [11-13]. Checkerboards assessing optimum
concentrations of various drugs in combination were per-
formed by diluting trans-mirincamycin (MIR 27.43 to
20,000 ng/ml) vertically and either chloroquine (CQ 3.43 to
2,500 ng/ml), tafenoquine (TQ 34.29 to 25,000 ng/ml) or
dihydroartemisinin (DHA 0.02 – 15 ng/ml) horizontally in
a three-fold serial dilution using a standard 8x8 well design
on microtiter plates.
In addition single compounds were testes with fresh
P. falciparum field isolates in the presence of three-fold
serial dilutions of the anti-malarial drugs trans-mirinca-
mycin (MIR; 137.2 to 100,000 ng/ml), clindamycin
(CLM; 68.6 to 50,000 ng/ml), azithromycin (AZM; 68.6
to 50,000 ng/ml), dihydroartemisinin (DHA; 0.034 to
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ine (QNN; 3.4 to 2,500 ng/ml) and mefloquine (MEF; 0.3
to 250 ng/ml) and subsequently growth inhibition was
quantified in a HRP2 ELISA. In a subset of samples trans-
mirincamycin and clindamycin were also tested after 24 h
incubation using the WHO microtest [14].
Data analysis
The 50 and 90% inhibitory concentrations (IC50s and IC90s,
respectively) were calculated from optical density readings
by nonlinear regression analysis. ICs were used to calculate
fractional inhibitory concentrations (FICs) as previously de-
scribed [11,13]. Isobolograms were plotted to demonstrate
synergism (FIC < 0.5) and/or antagonism (FIC > 2) for drug
combinations. Activity correlations were calculated by non-
parametric correlation analysis (Spearman).
Results
Results of mirincamycin in combination with DHA, CQ
and TQ are shown in Table 1 and Figure 1. All combina-
tions with mirincamycin were additive with a slight trend
to synergism, with an overall geometric mean fractional in-
hibitory concentration at 50% inhibition (FIC50) of 0.78,
0.80 and 0.80 for TQ, DHA, and CQ, respectively. Antag-
onism was not detected for any of the tested field isolates
or clones. The highest level of synergism (i.e. the lowest
FICs) was found for the combination of tafenoquine with
mirincamycin at a ratio of 1:0.27 to 1:7.2 (mean 1:2.7). The
optimal combination ratios were 1:444.4 to 1:36,000 (meanTable 1 Results of mirincamycin in combination with DHA, CQ
IC50 (nM)
Tafenoquine – mirincamycin (n) TQ MIR
Field isolates (nb = 3) 2,962.85 2,357.12
3D7 (nc = 3) 1,348.48 19,539.36
K1 (nc = 2) 1,076.23 24,736.61
All tested isolates (n = 8) 1,829.64 8,135.69
DHA – mirincamycin (n) DHA MIR
Field isolates (nb = 4) 3.23 1,067.34
3D7 (nc = 3) 1.90 16,995.36
K1 (nc = 2) 1.09 8,669.49
All tested isolates (n = 9) 2.12 4,276.94
Chloroquine – mirincamycin (nb) CHL MIR
Field isolates (nb = 2) 128.99 1,365.01
3D7 (nc = 4) 28.27 23,288.21
K1 (nc = 2) 651.93 18,869.50
All tested isolates (n = 8) 90.54 10,871.57
aSynergy, <0.5; additivity, 0.5-2; antagonism,>2.
bn, no. of fresh field isolates tested.
cn, no. of repeats.
Geometric mean IC50 and IC90 in nM for mirincamycin (MIR), tafenoquine (TQ), chloroq
(ΣFIC) concentrations for P. falciparum field isolates and culture clones 3D7 (chloroquin1:10,755.5) and 1:2.7 to 1:216 (mean 1:64.5) for DHA and
CQ, respectively.
Out of a total of 55 patient samples 43 (78.2%; 95% con-
fidence interval [CI]: 64.6 to 87.8) were successfully tested
with a geometric mean parasite density of 7,646 per μL
(95% CI: 5,399 to 10,827). The geometric mean of the 50%
inhibitory concentration (IC50) for trans-mirincamycin
was 1,212.6 nM (N= 43; 95% CI: 703.9 to 2,088.9) and the
corresponding value for clindamycin was 880.4 nM (N=
43; 95% CI: 469.7 to 1,650.1). IC50, IC90, IC99 values with
95% confidence intervals for all drugs tested are shown in
Table 2. No correlation was found between parasite dens-
ity and inhibitory concentrations (IC50) of mirincamycin
(R = 0.14; P = 0.4) and clindamycin (R = 0.10; P = 0.5) sug-
gesting little influence of the inoculum size on the validity
of in vitro assays. Individual IC values were calculated for
all drugs tested in parallel and compared by nonparamet-
ric correlation analysis to determine potential cross-
sensitivity and/or cross-resistance patterns between the
drugs. Mirincamycin showed significant activity correl-
ation with clindamycin (R = 0.64; P = 0.0002; N = 28) and
azithromycin (R = 0.390; P = 0.040; N = 28) but no evi-
dence of a correlation with any of the other tested anti-
malarials (dihydroartemisinin: R = 0.269; P = 0.166; N = 28,
mefloquine: R = 0.031; P = 0.875; N = 28, quinine: R =
0.025; P = 0.901; N = 28 and chloroquine: R = 0.319; P =
0.098; N = 28).
IC50s for trans-mirincamycin and clindamycin were 111





9,027.36 15,653.18 0.56 0.50
2728.49 36,936.11 0.86 1.09
5,271.96 39,284.24 0.88 1.03
5,005.97 25,786.65 0.78 0.83
DHA MIR
13.0 20,101.72 0.81 0.69
4.78 34,781.20 0.86 0.85
2.86 27,749.81 0.71 0.95
6.65 25,925.12 0.80 0.83
CHL MIR
680.90 16,161.82 0.39 0.99
63.87 38,311.62 1,06 1.04
1,174.69 36,535.66 0.95 0.99
239.01 30,511.74 0.80 0.91
uine (CHL) and dihydroartemisinin (DHA) as well as the sum of fractional inhibitory
e-sensitive) and K1 (chloroquine-resistant) tested in checkerboards assays.
Figure 1 (See legend on next page.)
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Figure 1 Isobolograms of mirincamycin in combination with tafenoquine, dihydroartemisinin and chloroquine. Isobolograms for the
checkerboards assays of mirincamycin in combination with tafenoquine, dihydroartemisinin and chloroquine at various concentration ratios for all
successfully tested isolates at FIC50 level. All individual data points (pooled FIC50s) at various concentration ratios are presented on the left hand
side, isobolograms on the right side point out the geometric mean of the individual data points. The straight lines in each panel are representing
the type of interaction. Data points below the 0.5-line show synergism (FIC < 0.5), around the 1.0-line are additive (FIC 0.5-2) and above the 2-line
are antagonistic (FIC > 2).
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aria parasites.
Discussion
So far there is only limited evidence for the in vitro [6]
and ex vivo activity [9] of mirincamycin. P. cynomolgi ani-
mal models have proven that mirincamycin was curative
even when given as monotherapy [3,4]. Interestingly, the
substance seems to show considerable activity against hyp-
nozoites [4], and may enhance the effect of primaquine
when given in combination [5].
For the first time, these results prove that mirincamycin
has an additive mode of interaction in vitro with a slight
trend to synergism when combined with various standard
anti-malarials. Similar drug interaction profiles were found
2003 by Ramharter et al. for clindamycin in combination
with DHA where effective concentrations of clindamycin
were comparable to our results for mirincamycin [15]. Sub-
sequently conducted clinical trials have proven high efficacy
of clindamycin in combination with conventional anti-
malarial drugs [16]. Clinical studies will need to show in
how far this is also the case for mirincamycin.
8-aminoquinolines (like primaquine and tafenoquine)
can cause severe haemolysis in individuals with G6PD de-
ficiency. The challenge is therefore either to improve the
efficacy and thereby potentially reduce the dose of 8-
aminoquinolines with new combination partners possibly
resulting in a reduced risk of haemolysis or to overcome
this side effect with safer replacement drugs.
Mirincamycin alone or in combination (e.g. with 8-
aminoquinolines) may be a promising candidate forTable 2 Geometric mean inhibitory concentration of various dru
Antiplasmodial activity [nm] (95% CI)
Drug (na)b IC50 (95% CI) IC9
MIR (n = 43) 1,212.6 (703.9 – 2088.9) 12,1
CLI (n = 43) 880.4 (469.7 – 1650.1) 12,0
AZM (n = 43) 4,082.6 (2947.5 – 5654.8) 21,7
DHA (n = 42) 0.9 (0.7 – 1.1) 2.9
CHL (n = 42) 102.6 (78.0 –134.9) 370
QNN (n = 42) 61.2 (46.6 – 80.2) 289
MEF (n = 42) 13.6 (9.3 – 20.0) 64.9
an, no. of fresh field isolates tested.
bMIR, mirincamycin; CLI, clindamycin; AZM, azithromycin; DHA, dihydroartemisinin;malaria prophylaxis in nonimmune subjects, such as tour-
ists and soldiers and could potentially help to enhance the
hypnozoitocidal activity of 8-aminoquinolines by concomi-
tant administrion, as previously demonstarted in a P. cyno-
molgi model [4,5]. A lower dose could potentially also
result in improved safety of 8-aminoquinolines (e.g. in
glucose-6-phosphatedehydrogenase-deficient subjects).
Limitations of this study include all potential short-
comings of an in vitro study as well as the potential
bias arising from the fact that only P. falciparum has
been tested which cannot be extrapolated to P. vivax
or P. ovale in the absence of a well-established culture
model [17]. Also among 8-aminoquinolines only tafe-
noquine was tested in this study, which in recent stud-
ies has demonstrated high efficacy in the treatment
and relapse prevention of vivax malaria in combination
with chloroquine [18]. However, currently primaquine
remains the only 8-aminoquinolone widely used for
P. vivax radical cure.
Conclusions
The study showed that mirincamycin has additive to
synergistic interaction in combination with different
classes of anti-malarials, exhibits no activity correlation
with traditional anti-malarials and exerts substantial
anti-malarial activity on its own. As a consequence
mirincamycin may be a potential candidate for clinical
exploration either in combination with faster acting
anti-malarials in the treatment of multidrug-resistant
falciparum malaria or in combination with other drugs
for the treatment of non-falciparum malaria.gs against fresh P. falciparum isolates from Bangladesh
0 (95% CI) IC99 (95% CI)
16.4 (6296.4 – 23 316.0) 34,329.2 (18 895.1 – 62 370.2)
74.7 (6470.9 – 22 531.2) 36,581.3 (24 386.7 – 54 873.9)
81.4 (17 004.1 – 27 901.0) 39,979.5 (26 901.2 – 59 415.9)
(2.2 – 4.0) 4.8 (3.3 – 6.9)
.6 (279.1 – 492.1) 651.2 (467.1 – 907.9)
.4 (236.2 – 354.7) 538.5 (421.2 – 688.5)
(47.1 – 89.3) 272.7 (38.1 – 1953.9)
CHL, chloroquine; QNN, quinine; MEF, mefloquine.
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